Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Amortization of Deferred Charges (2016 - 2020)

Historic Amortization of Deferred Charges for Outlook Therapeutics (OTLK) over the last 6 years, with Q2 2020 value amounting to $99849.0.

  • Outlook Therapeutics' Amortization of Deferred Charges fell 7617.34% to $99849.0 in Q2 2020 from the same period last year, while for Jun 2020 it was $235636.0, marking a year-over-year decrease of 8351.82%. This contributed to the annual value of $2.7 million for FY2024, which is 600.9% up from last year.
  • Per Outlook Therapeutics' latest filing, its Amortization of Deferred Charges stood at $99849.0 for Q2 2020, which was down 7617.34% from $120065.0 recorded in Q1 2020.
  • Outlook Therapeutics' Amortization of Deferred Charges' 5-year high stood at $1.7 million during Q3 2017, with a 5-year trough of $2504.0 in Q2 2016.
  • For the 5-year period, Outlook Therapeutics' Amortization of Deferred Charges averaged around $405344.2, with its median value being $230217.0 (2018).
  • As far as peak fluctuations go, Outlook Therapeutics' Amortization of Deferred Charges soared by 5311098.24% in 2017, and later tumbled by 9650.92% in 2019.
  • Over the past 5 years, Outlook Therapeutics' Amortization of Deferred Charges (Quarter) stood at $140820.0 in 2016, then skyrocketed by 311.58% to $579586.0 in 2017, then fell by 22.29% to $450381.0 in 2018, then crashed by 96.51% to $15722.0 in 2019, then surged by 535.09% to $99849.0 in 2020.
  • Its Amortization of Deferred Charges was $99849.0 in Q2 2020, compared to $120065.0 in Q1 2020 and $15722.0 in Q4 2019.